Avalo Therapeutics Quarterly Cash Flow Statement
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.65+0.22 (+1.64%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Avalo Therapeutics generated -$20.0 million of operating cash flow. That left free cash flow of -$20.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Avalo Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -36.36M | -19.63M | -13.72M | -30.63M | -20.77M | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M | -5.23M |
| Net Income growth (YoY) | — | — | — | -232.94% | -121.09% | — | — | — | — | — | — | -263.78% |
| Depreciation & Amortization | 17.00K | 17.00K | 16.00K | 59.00K | 134.00K | 135.00K | 68.00K | 34.00K | 33.00K | 34.00K | 43.00K | 41.00K |
| Stock-Based Compensation | 5.30M | 3.58M | 4.51M | 3.15M | 2.72M | 3.24M | 2.90M | 1.85M | 471.00K | 629.00K | 776.00K | 953.00K |
| Change in Working Capital | 2.07M | 447.00K | -5.11M | -2.13M | 1.61M | 2.89M | -1.13M | -624.00K | -1.70M | 417.00K | -333.00K | 376.00K |
| Operating Cash Flow | -19.99M | -17.69M | -14.25M | -16.36M | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.20M | -2.77M | -6.84M |
| Capital Expenditures | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | -329.93M | 25.50M | 2.40M | -13.26M | -70.86M | 0 | 0 | 0 | 0 | 356.00K | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | — | — | 0 | -15.24M |
| Financing Cash Flow | 410.21M | 1.40M | 687.00K | 14.37M | -469.00K | 0 | 67.71M | 0 | -472.00K | 108.61M | 1.00K | 10.70M |
| Net Change in Cash | 60.30M | 9.21M | -11.16M | -15.26M | -82.72M | -9.46M | 52.66M | -11.53M | -16.75M | 102.77M | -2.77M | 3.86M |
| Free Cash Flow | -19.99M | -17.69M | -14.25M | -16.36M | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.20M | -2.77M | -6.84M |
This table shows 12 quarterly periods of Avalo Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVTX's reporting calendar. What is a cash flow statement?